Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5594248 | 1.00 | PTGS2 (0.51) | PTGS2PTGS1CYP3A4CA1CA2 | |
| SCHEMBL5594845 | 0.91 | PTGS2 (0.50) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL5594787 | 0.91 | PTGS2 (0.50) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL8591714 | 0.90 | PTGS2 (0.40) | PTGS2CYP3A4CA1CA2CA4 | |
| SCHEMBL5594146 | 0.90 | PTGS2 (0.51) | PTGS2PTGS1CYP3A4CA1CA2 | |
| SCHEMBL5593830 | 0.84 | PTGS2 (0.56) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL5593951 | 0.84 | PTGS2 (0.56) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL5594117 | 0.81 | PTGS2 (0.55) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL5594943 | 0.81 | PTGS2 (0.55) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL5594573 | 0.81 | PTGS2 (0.62) | PTGS2PTGS1CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220770-B2 | Heterocyclo-substituted imidazoles for the treatment of inflammation | KHANNA ISH K | 2007-05-22 | — | — | US | disclosed |
| US-20050256120-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | KHANNA ISH K | 2005-11-17 | — | — | US | disclosed |
| US-20050096368-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | G.D. SEARLE & CO. | 2005-05-05 | — | — | US | disclosed |
| US-6613789-B2 | Especially for treating arthritis, pain and fever | G. D. SEARLE & CO. | 2003-09-02 | — | — | US | disclosed |
| US-20030036557-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | G.D. SEARLE & CO. | 2003-02-20 | — | — | US | disclosed |
| EP-1193265-A2 | A process for the preparation of 4-[2-(aryl or heterocyclo)-1H-imidazol-1-yl]benzenesulfonamides | G.D. Searle & Co. (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-0772600-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003388-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256120-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | LTC4S, HRH4, LTB4R2 | PTGS2 107/4885PTGS1 144/4885CYP3A4 196/4885 |
| US-20030036557-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | HCK, IL4I1, AHR | PTGS2 98/4885PTGS1 117/4885CYP3A4 374/4885 |
| US-20050096368-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | HRH4, LTC4S, HCAR3 | PTGS2 150/4885PTGS1 201/4885CYP3A4 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.